射频治疗肝癌、肺癌后机体反应及用药探讨

Evaluation of the host response after the treatment of radio frequency ablation in patients with liver or lung cancer and antimicrobial usage principles

目的 了解肝癌及肺癌患者经射频治疗后的体温、血象变化 ,与治疗点数的关系 ,以探讨射频治疗前预防使用抗菌药物的原则。方法 对治疗的肺癌患者 2 6人 (30例次 )和肝癌患者 2 9人 (4 0例次 )的射频点数、体温、血象进行统计分析。结果 射频治疗 70例次有 37例次发热 ,其中 30例次伴有白细胞升高 ,31例次体温 <39℃ ,32例次持续发热时间 <6d。结论 射频治疗后 5 2 .86 %的患者出现体温升高 ,时间在 6d以内 ,白细胞升高 ,考虑为射频治疗后反应 ,仅给予围术期用药即可。如体温 >39℃ ,持续时间 >6d ,应给予联合强有力抗菌药物治疗。

Objective To study the relation between change in body temperature or hemogram and therapeutic count of radio frequency ablation (RFA) in treating patients with liver or lung cancer, and to evaluate the principles of preventive antimicrobial administration before RFA treatment. Methods The therapeutic count, body temperature and blood count of 26 patients (30 times) with lung cancer and 29 patients (40 times) with liver cancer were analysed. Results Thirty seven of 70 cases developed fever after treatment, 30 of which were associated with an increase in leukocytes, temperature of 31 cases was lower than 39℃, 32 cases had fever which lasted less than 6 days. Conclusion 52.86% of patients had fever after treatment of RFA, the slightly increase of leukocytes within 6 days could be considered the response of the treatment, and patients should only receive perioperative antimicrobial agents, if body temperature was above 39℃, and lasted more than 6 days, combination of antimicrobial agents should be used.